Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582243 | 0.94 | ALDH1A1 (0.33) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1352447 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TSHR | |
| SCHEMBL1012045 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL6472790 | 0.79 | TSHR (0.39) | ALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL1352707 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| Water SCHEMBL28821923 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL15800756 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TSHRARG2 | |
| SCHEMBL15694681 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL31040519 | 0.73 | LMNA (0.42) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL2639383 | 0.73 | SMN1; SMN2 (0.37) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536228-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2013-09-17 | — | — | US | claimed |
| US-7893285-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2011-02-22 | — | — | US | claimed |
| US-7888393-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2011-02-15 | — | — | US | claimed |
| US-20100227929-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-09-09 | — | — | US | claimed |
| US-20100197795-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-08-05 | — | — | US | claimed |
| US-20090169610-A1 | Liposome Preparation | SIEMENS AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | US | claimed |
| EP-1980243-A1 | LIPOSOME PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-15 | — | — | EP | claimed |
| US-20070286896-A1 | Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2007-12-13 | — | — | US | claimed |
| US-20070160657-A1 | Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2007-07-12 | — | — | US | claimed |
| US-20060193906-A1 | Sugar-modified liposome and products comprising the liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2006-08-31 | — | — | US | claimed |
| EP-1655038-A1 | TARGET-DIRECTED AND ENTERIC ABSORPTION-CONTROLLED LIPOSOME HAVING SUGAR CHAIN AND CANCER REMEDY AND DIAGNOSTIC CONTAINING THE SAME | National Institute of Advanced Industrial Science and Technology (JP) | 2006-05-10 | — | — | EP | claimed |
| EP-1655022-A1 | REMEDY OR DIAGNOSTIC FOR INFLAMMATORY DISEASE CONTAINING TARGET-DIRECTING LIPOSOME | National Institute of Advanced Industrial Science and Technology (JP) | 2006-05-10 | — | — | EP | claimed |
| US-9084821-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130251763-A1 | TRANSDERMAL COMPOSITIONS | MICRODERMIS CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8536228-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130011466-A1 | LIPOSOME ENCAPSULATING AMMINE-PLATINUM COMPLEX AT HIGH CONCENTRATION, AND METHOD FOR PRODUCTION OF THE LIPOSOME | KATAYAMA CHEMICAL INDUSTRIES CO., LTD. (JP) | 2013-01-10 | — | — | US | disclosed |
| EP-1655038-A1 | TARGET-DIRECTED AND ENTERIC ABSORPTION-CONTROLLED LIPOSOME HAVING SUGAR CHAIN AND CANCER REMEDY AND DIAGNOSTIC CONTAINING THE SAME | National Institute of Advanced Industrial Science and Technology (JP) | 2006-05-10 | — | — | EP | disclosed |
| EP-1655022-A1 | REMEDY OR DIAGNOSTIC FOR INFLAMMATORY DISEASE CONTAINING TARGET-DIRECTING LIPOSOME | National Institute of Advanced Industrial Science and Technology (JP) | 2006-05-10 | — | — | EP | disclosed |
| US-20040122105-A1 | Transdermal compositions | DRSS GLOBAL, LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026259-A2 | TRANSDERMAL COMPOSITIONS | BETTLE GRISCOM III (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251763-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | ALDH1A1 2659/4885TSHR 3358/4885SMN1; SMN2 4798/4885 |
| US-20130011466-A1 | LIPOSOME ENCAPSULATING AMMINE-PLATINUM COMPLEX AT HIGH CONCENTRATION, AND METHOD FOR PRODUCTION OF THE LIPOSOME | SLC7A1, MLEC, PHOSPHO1 | ALDH1A1 3725/4885TSHR 3243/4885SMN1; SMN2 3051/4885 |
| US-20100197795-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, DGKG | ALDH1A1 2629/4885TSHR 3464/4885SMN1; SMN2 4812/4885 |
| US-20100227929-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | ALDH1A1 2659/4885TSHR 3358/4885SMN1; SMN2 4798/4885 |
| US-20040122105-A1 | Transdermal compositions | S100A10, DGKG, COX6C | ALDH1A1 2002/4885TSHR 4174/4885SMN1; SMN2 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.